For years, fibromyalgia was a medical enigma, often dismissed as a psychological complaint rather than a legitimate disease. Sufferers endured chronic pain, fatigue, and brain fog, only to face skepticism from doctors and loved ones. However, groundbreaking research led by Dr. Bruce Gillis, a Harvard-trained physician, has transformed our understanding of this condition, revealing its roots in immune system dysfunction, and offering hope to millions through innovative diagnostics and potential treatments.
A fibromyalgia breakthrough in immune system research
Dr. Gillis’s pivotal work, initiated at the University of Illinois College of Medicine’s Department of Pathology, began reshaping fibromyalgia’s narrative in 2012. His team discovered that patients exhibit abnormalities in peripheral blood mononuclear cells (PBMCs), critical white blood cells responsible for producing essential proteins, particularly cytokines, which regulate immune responses. In fibromyalgia patients, these cells are defective, leading to significantly lower cytokine levels compared to healthy individuals. “We found an incredible set of changes in immune system proteins called chemokines and cytokines in the patients with fibromyalgia,” Gillis stated, emphasizing the clarity of these findings. Citation 1
This discovery was based on a comparative study of immune cells from fibromyalgia patients and healthy controls (individuals without fibromyalgia), revealing unequivocal differences. A larger follow-up study confirmed that most cytokine concentrations in fibromyalgia patients were notably reduced, a hallmark that distinguished them from healthy counterparts. Citation 2
These findings laid the foundation for the FM/a Test, the first blood test designed to diagnose fibromyalgia by evaluating these immune biomarkers. The test’s development marked a turning point, offering objective validation for a condition long shrouded in doubt.
You can hear my interview with Dr. Gillis wherever you get your podcasts or watch it on YouTubehttps://youtu.be/9v7qGfMhcqw.
Genomic insights deepen understanding about fibromyalgia
Building on this work, recent studies have employed high-throughput RNA sequencing to uncover unique genomic signatures in fibromyalgia patients. A 2024 study, published in Nature Scientific Reports, analyzed PBMCs from 96 fibromyalgia patients and 93 controls, identifying 1,720 differentially expressed genes. These signatures, absent in healthy individuals, point to genetic heterogeneity within fibromyalgia, involving disrupted inflammatory pathways, extracellular matrix issues, and heightened interferon signaling.
The researchers noted, “To our knowledge, this is the first study to report genetic heterogeneity within FM patients,” highlighting its implications for personalized treatments. Citation 3
These genomic findings not only reinforce fibromyalgia’s biological basis but also suggest potential hereditary factors, paving the way for future research into genetic predispositions. Such insights are crucial for developing targeted therapies that address the root causes rather than merely masking symptoms.
The FM/a test: A fibromyalgia diagnostic revolution
The FM/a Test, commercialized following Gillis’s 2012 findings, has been a game-changer. By detecting specific cytokine deficiencies, it provides a reliable method to confirm fibromyalgia, shifting its perception from a subjective syndrome to a medically validated condition. The test’s significance resonates deeply with patients.
However, the test is not without critique. A 2015 study compared fibromyalgia patients with those having lupus and rheumatoid arthritis, noting some overlap in immune profiles, which suggests caution in differential diagnosis. Citation 5
Critics have called for larger testing cohorts to refine specificity, yet the test’s contributions were recognized with an award from the American Association for Clinical Chemistry, underscoring its scientific rigor. Citation 1
In 2024, EpicGenetics, Gillis’s company, settled a lawsuit over misleading claims about the test’s definitiveness, leading to its discontinuation, though the underlying research remains influential. The new test is the FM1 test. Citation 6
Broader implications and connections
The immune dysfunction uncovered in fibromyalgia extends beyond the condition itself. Research indicates that 86% of long COVID patients share similar immune markers, suggesting a viral trigger, such as coronaviruses, may exacerbate fibromyalgia’s immune irregularities.
Dr. Leonard Calabrese of the Cleveland Clinic warns, “The connections between long COVID and fibromyalgia are frightening and warrant urgent research.” Citation 7
This overlap hints at fibromyalgia as part of a broader spectrum of immune-mediated disorders, including chronic fatigue syndrome and interstitial cystitis.
The human cost is staggering. Fibromyalgia patients face a suicide risk up to 48 times higher than healthy individuals, with 81.8% experiencing suicide ideation due to chronic pain and societal invalidation. Citation 8
Patient Chris, a 21-year-old, shares, “The constant pain affects everything — work, relationships. Being open about my fibromyalgia helps, but it’s hard when people don’t believe you.” Citation 9
Toward a new era of fibromyalgia treatment
Current treatments, like duloxetine and pregabalin, focus on symptom relief but often fall short. Citation 10
Gillis’s research has spurred exploration into therapies targeting immune dysfunction, such as compounds to stimulate PBMC protein production, though none are yet widely available. Citation 11
The 2025 FDA approval of Tonmya, a sublingual non-opioid, marks progress in addressing pain and fatigue more effectively. Citation 12
A natural solution for fibromyalgia
“I was able to identify a compound that causes those defective white blood cells to increase the production of those proteins and when that happens, their symptoms either lessen or they vanish. That compound is called Imbixx. you can learn about it by going to imbxxcom (where you can hear stories from real patients). It is a totally natural compound. As it turns out, I was able to develop it based upon anti-cancer chemotherapy research that was done about 20 to 30 years ago, and we were able to identify a family of bacteria that are found in soil and water that, when acting with those defective white blood cells, cause those white blood cells to increase the production of those proteins.” Dr. Bruce Gillis
A legacy of fibromyalgia validation
Dr. Gillis’s work, published in peer-reviewed journals like BMC Clinical Pathology in 2012, has redefined fibromyalgia’s diagnostic and therapeutic landscape. Citation 2
His research not only validates the experiences of millions but also challenges the stigma that fibromyalgia is a “women’s disease”— it affects men and children too.
Fibromyalgia’s immune secrets are no longer hidden. With ongoing genetic research and emerging treatments, the path forward is clearer, offering patients validation and the promise of a better quality of life.
Citations
Citations
- EpicGenetics: Laboratory-Developed Tests — Center for Science in the Public Interest
https://www.cspi.org/case/epicgenetics-laboratory-developed-tests - STAT News: EpicGenetics agrees to stop selling two questionable blood tests
https://www.statnews.com/2024/08/23/epicgenetics-fibromyalgia-test-lawsuit-settled-with-cspi-bruce-gillis/ - CSPI press release: CSPI sues EpicGenetics, maker of test for fibromyalgia, for false and misleading claims
https://www.cspi.org/press-release/cspi-sues-epicgenetics-maker-test-fibromyalgia-false-and-misleading-claims - Settlement agreement PDF
https://www.cspi.org/sites/default/files/2024-08/2024%2007%2030%20FMa%20Test%20Settlement%20Agreement_final%20fully%20executed%20version.pdf - KFF Health News: After False Advertising Accusation, EpicGenetics Halts 2 Blood Test Sales
https://kffhealthnews.org/morning-breakout/after-false-advertising-accusation-epicgenetics-halts-2-blood-test-sales/ - BusinessWire: Epicgenetics New Collaboration with the University of Illinois
https://www.businesswire.com/news/home/20220425005972/en/Epicgenetics-New-Collaboration-with-the-University-of-Illinois - Support Fibromyalgia: Fibromyalgia Blood Test Lawsuit
https://supportfibromyalgia.org/fibromyalgia-blood-test-lawsuit/ - STAT News: Consumer watchdog sues diagnostic firm EpicGenetics
https://www.statnews.com/2023/10/04/consumer-watchdog-sues-diagnostic-firm-epicgenetics-alleging-misleading-claims-about-fibromyalgia-test/